[{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sosei Group Corporation"},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi to Develop Prophylactic Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Shionogi"},{"orgOrder":0,"company":"Kao Corporation","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Lead Optimization trial for Soil-transmitted\n helminths Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Kao Corporation"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.07 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Hit Identification trial for Chagas disease,\n Leishmaniasis Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Daiichi Sankyo"},{"orgOrder":0,"company":"Epsilon Molecular Engineering","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Series A Financing of 570 Million Yen Procured by Epsilon Molecular Engineering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Epsilon Molecular Engineering"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Shionogi","sponsor":"Nagasaki University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Drugs with Nagasaki University and MMV, Supported by the GHIT Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Shionogi"},{"orgOrder":0,"company":"Shionogi","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Shionogi"},{"orgOrder":0,"company":"bitBiome","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"bitBiome and Kaken Pharmaceuticals Sign Joint Research Agreement on The Discovery of Drugs for Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"bitBiome"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the agreement, the companies will utilize the microbial platform technology developed by bitBiome to obtain drug candidates for the treatment of infectious diseases with high unmet medical needs.
The funding will be used for the research and development of novel antimalarial drugs by Takeda and MMV. The investment will help identify multiple promising compounds in the early stages of research and development.
Under the terms of the collaboration, Shionogi, Nagasaki University and MMV will accelerate the evaluation and the development of new drugs for the treatment of malaria.
The funding will be used to accelerate the evaluation and the development of new drugs for the treatment of malaria by Shionogi, Nagasaki University and MMV.
The funding will be used to advance the pre-clinical development of the SH-879, Company’s novel oral anti-viral small molecules targeting the main protease of SARS-CoV-2 (Mpro), an enzyme critical to SARS-CoV-2 replication, as potential treatments for COVID-19.
With these investments, Epsilon Molecular Engineering plans to further promote its next-generation biotechnology-based drug discovery research and development focusing on heavy chain single domain antibodies, VHH antibody.
Funds will be used for Cry5B optimization for Trichuris - whipworm which is beign conducted by Kao Corporation, PATH, University of Massachusetts Medical School.
In a project supported by the Japan Agency for Medical Research and Development (AMED), Shionogi and its subsidiary, UMN Pharma, are pursuing the discovery and development of a recombinant protein vaccine for COVID-19, using their unique technology.
Lead Product(s):
Prophylactic recombinant protein vaccine
Company has initiated a new R&D program to identify novel compounds that block the activity of the SARS-CoV-2 MPro protease (Nsp5), which has been designated as potential target for drug development.